Suppr超能文献

[儿童蒽环类药物晚期心脏毒性的评估]

[Evaluation of late cardiac toxicity of anthracycline in childhood].

作者信息

Butera G, Piciacchia D, Chessa M, Condoluci C, Tornesello A, Delogu A B, Mastrangelo S, Cipriani A

机构信息

Sezione Autonoma di Cardiologia Pediatrica, Università Cattolica del Sacro Cuore, Roma.

出版信息

Minerva Pediatr. 1998 Apr;50(4):111-9.

PMID:9808963
Abstract

OBJECTIVES

To examine left ventricular function in patients previously treated with anthracycline for childhood malignancies. To evaluate the importance of age at the beginning of therapy, of total cumulative dose and of length of follow-up on late cardiac effects of anthracyclines.

DESIGN

Cross sectional echocardiography study of left ventricular function.

PATIENTS

Eighteen patients surviving between 1 and 9 years (median 2 years) from end of chemotherapy. Cumulative doses were between 120 and 550 mg/mq (median 275 mg/mq). Age at the beginning of chemotherapy was between 1.8 and 12.25 years (median 5.17 years). Nineteen healthy subjects were also studied as control group.

METHODS

Assessment of transmitral diastolic pulsed wave Doppler flow patterns and of transaortic pulsed wave Doppler flow patterns. Evaluation of systolic function measured by M-mode echocardiography.

RESULTS

Patients compared to controls showed a significative reduction of Ejection Fraction, of Shortening Fraction, of peak early phase to peak atrial phase filling velocity ratio and an increase of peak atrial phase filling velocity and of time-velocity integral of peak filling atrial phase. These alterations were more evident at doses higher than 250 mg/m2, in patients whose therapy started before 5 years of age and in patients whose follow-up was longer than 5 years.

CONCLUSIONS

Significant abnormalities of systolic and diastolic function may appear some years after the end of anthracycline therapy for childhood malignancies. Therefore patient's continued follow-up is necessary in order to guide patient care and to better chemotherapeutic protocols.

摘要

目的

研究曾接受蒽环类药物治疗儿童恶性肿瘤的患者的左心室功能。评估治疗开始时的年龄、总累积剂量及随访时间对蒽环类药物晚期心脏效应的重要性。

设计

左心室功能的横断面超声心动图研究。

患者

18例化疗结束后存活1至9年(中位值2年)的患者。累积剂量在120至550mg/m²之间(中位值275mg/m²)。化疗开始时的年龄在1.8至12.25岁之间(中位值5.17岁)。还研究了19名健康受试者作为对照组。

方法

评估二尖瓣舒张期脉冲波多普勒血流模式及主动脉脉冲波多普勒血流模式。通过M型超声心动图评估收缩功能。

结果

与对照组相比,患者的射血分数、缩短分数、舒张早期峰值与心房期峰值充盈速度之比显著降低,心房期峰值充盈速度及心房期峰值充盈的时间-速度积分增加。这些改变在累积剂量高于250mg/m²、5岁前开始治疗以及随访时间超过5年的患者中更为明显。

结论

儿童恶性肿瘤患者接受蒽环类药物治疗结束数年后,可能会出现显著的收缩和舒张功能异常。因此,有必要对患者进行持续随访,以指导患者护理并优化化疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验